{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+Muscular+Atrophy&page=4",
    "query": {
      "condition": "Spinal Muscular Atrophy",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 194,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+Muscular+Atrophy&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spinal+Muscular+Atrophy&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T03:07:31.194Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05776862",
      "title": "Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Tetraplegia",
        "Paraplegia",
        "Muscle Loss",
        "Atrophy, Muscular",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Ursolic Acid",
          "type": "DRUG"
        },
        {
          "name": "Strength Training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-03-27",
      "completion_date": "2025-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05776862"
    },
    {
      "nct_id": "NCT07521930",
      "title": "Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tetraplegia/Tetraparesis",
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Muscular Disorders, Atrophic",
        "Brain Stem Stroke",
        "Spinal Cord Injuries (SCI)",
        "Muscular Dystrophies",
        "Muscular Atrophy, Progressive",
        "Pontine Hemorrhage",
        "Pontine Infarction"
      ],
      "interventions": [
        {
          "name": "INTENT Neural Interface System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 5,
      "start_date": "2027-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07521930"
    },
    {
      "nct_id": "NCT06532474",
      "title": "Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "5 Years to 20 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-10-29",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06532474"
    },
    {
      "nct_id": "NCT02574390",
      "title": "Answer ALS: Individualized Initiative for ALS Discovery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Primary Lateral Sclerosis",
        "Flail Arm ALS",
        "Progressive Muscular Atrophy",
        "Monomelic Amyotrophy",
        "Motor Neuron Disease",
        "Asymptomatic ALS Gene Carriers",
        "Healthy Controls"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1049,
      "start_date": "2015-12",
      "completion_date": "2020-01-01",
      "has_results": false,
      "last_update_posted_date": "2020-01-13",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574390"
    },
    {
      "nct_id": "NCT05067790",
      "title": "A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "15 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-01-21",
      "completion_date": "2027-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Owosso",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05067790"
    },
    {
      "nct_id": "NCT00878436",
      "title": "Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 52,
      "start_date": "2009-06",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2018-02-07",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 4,
      "location_summary": "New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00878436"
    },
    {
      "nct_id": "NCT05062174",
      "title": "Breast Cancer BRCA1 Carriers: a Pilot Study",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "BRCA1 Mutation",
        "High-grade Serous Ovarian Cancer",
        "TNBC - Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Mifepristone 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Prophylactic mastectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2021-11-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-12-15",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 2,
      "location_summary": "Carmel, Indiana • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05062174"
    },
    {
      "nct_id": "NCT05152823",
      "title": "Gene Therapy for IGHMBP2-Related Diseases",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SMARD1",
        "CMT2S"
      ],
      "interventions": [
        {
          "name": "Gene Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Megan Waldrop",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "2 Months to 14 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-11-04",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05152823"
    },
    {
      "nct_id": "NCT07444450",
      "title": "A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscular Atrophy, Spinal"
      ],
      "interventions": [
        {
          "name": "Salanersen",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "7 Months",
        "sex": "ALL",
        "summary": "0 Days to 7 Months"
      },
      "enrollment_count": 42,
      "start_date": "2026-10-31",
      "completion_date": "2033-07-26",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 1,
      "location_summary": "Flower Mound, Texas",
      "locations": [
        {
          "city": "Flower Mound",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444450"
    },
    {
      "nct_id": "NCT02644668",
      "title": "A Study of CK-2127107 in Patients With Spinal Muscular Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Reldesemtiv 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Reldesemtiv 450 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cytokinetics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2016-01-14",
      "completion_date": "2018-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-08-31",
      "last_synced_at": "2026-10-21T03:07:31.194Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02644668"
    }
  ]
}